- Current report filing (8-K)

 

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):		September 1, 2010

Martek Biosciences Corporation
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	0-22354	52-1399362
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
6480 Dobbin Road, Columbia, Maryland		21045
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code:		410-740-0081

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Top of the Form

Item 2.02 Results of Operations and Financial Condition.

On September 1, 2010, Martek issued a press release announcing its financial results for the fiscal quarter ended July 31, 2010. A copy of Martek’s press release is furnished as Exhibit 99.1 to this Item 2.02.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following is furnished as an Exhibit to this Current Report on Form 8-K.

Exhibit No. 99.1

Press Release dated September 1, 2010 issued by Martek Biosciences Corporation (Furnished pursuant to Item 2.02)

---

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Martek Biosciences Corporation
September 1, 2010		By:		/s/ Peter L. Buzy
				Name: Peter L. Buzy
				Title: Chief Financial Officer, Treasurer and Executive Vice President for Finance and Administration

---

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated September 1, 2010 issued by Martek Biosciences Corporation (Furnished pursuant to Item 2.02)